Clinical data
Trade names Persantine, Curantyl
AHFS/Drugs.com Monograph
MedlinePlus a682830
  • B
Routes of
By mouth, IV
ATC code B01AC07 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 37–66%[1]
Protein binding ~99%
Metabolism Liver (glucuronidation)[2]
Biological half-life α phase: 40 min,
β phase: 10 hours
Excretion Biliary (95%), urine (negligible)
CAS Number 58-32-2 YesY
PubChem (CID) 3108
DrugBank DB00975 YesY
ChemSpider 2997 YesY
KEGG D00302 YesY
ECHA InfoCard 100.000.340
Chemical and physical data
Formula C24H40N8O4
Molar mass 504.626 g/mol
3D model (Jmol) Interactive image

Dipyridamole (trademarked as Persantine and Curantyl) is a medication that inhibits blood clot formation[3] when given chronically and causes blood vessel dilation when given at high doses over a short time.

Mechanism and effects

Medical uses

Use in individuals with a history of stroke

A combination of dipyridamole and aspirin (acetylsalicylic acid/dipyridamole) is FDA-approved for the secondary prevention of stroke and has a bleeding risk equal to that of aspirin use alone.[4] Dipyridamole absorption is pH-dependent and concomitant treatment with gastric acid suppressors (such as a proton pump inhibitor) will inhibit the absorption of liquid and plain tablets.[7][8] Modified release preparations are buffered and absorption is not affected.[9][10]

However, it is not licensed as monotherapy for stroke prophylaxis, although a Cochrane Review suggested that dipyridamole may reduce the risk of further vascular events in patients presenting after cerebral ischemia.[11]

A triple therapy of aspirin, clopidogrel, and dipyridamole has been investigated, but this combination led to an increase in adverse bleeding events.[12]

Other uses

Dipyridamole also has non-medicinal uses in a laboratory context, such as the inhibition of cardiovirus growth in cell culture.


Dipyridamole overdose
Classification and external resources
Specialty emergency medicine
ICD-10 T46.3
ICD-9-CM 972.4
DiseasesDB 3840

Dipyridamole overdose can be treated with aminophylline[2]:6 which reverses its dilating effect on the blood vessels. Symptomatic treatment is recommended, possibly including a vasopressor drug. Gastric lavage should be considered. Administration of xanthine derivatives (e.g., aminophylline) may reverse the hemodynamic effects of dipyridamole overdose. Since dipyridamole is highly protein bound, dialysis is not likely to be of benefit.

See also


  1. Nielsen-Kudsk, F; Pedersen, AK (May 1979). "Pharmacokinetics of Dipyridamole". Acta Pharmacologica et Toxicologica. 44 (5): 391–9. PMID 474151.
  2. 1 2 "Aggrenox (aspirin/extended-release dipyridamole) Capsules. Full Prescribing Information" (PDF). Boehringer Ingelheim Pharmaceuticals, Inc. Retrieved 1 December 2016.
  3. "Dipyridamole" at Dorland's Medical Dictionary
  4. 1 2 3 Brown DG, Wilkerson EC, Love WE (March 2015). "A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons". Journal of the American Academy of Dermatology. 72 (3): 524–34. doi:10.1016/j.jaad.2014.10.027. PMID 25486915.
  5. Dixon BS, Beck GJ, Vazquez MA, et al. (2009). "Effect of dipyridamole plus aspirin on hemodialysis graft patency". N Engl J Med. 360 (21): 2191–2201. doi:10.1056/nejmoa0805840.
  6. Dipyridamole in the laboratory: Fata-Hartley, Cori L.; Ann C. Palmenberg. "Dipyridamole reversibly inhibits mengovirus RNA replication". doi:10.1128/JVI.79.17.11062-11070.2005. Retrieved 2007-02-13.
  7. Russell TL, Berardi RR, Barnett JL, O’Sullivan TL, Wagner JG, Dressman JB. pH-related changes in the absorption of "dipyridamole" in the elderly. Pharm Res (1994) 11 136–43.
  8. Derendorf H, VanderMaelen CP, Brickl R-S, MacGregor TR, Eisert W. "Dipyridamole" bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol (2005) 45, 845–50.
  9. http://emc.medicines.org.uk/medicine/304/SPC/Persantin+Retard+200mg/#EXCIPIENTS
  10. Stockley, Ivan (2009). Stockley’s Drug Interactions. The Pharmaceutical Press. ISBN 0-85369-424-9.
  11. De Schryver EL, Algra A, van Gijn J (2007). Algra A, ed. "Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.". Cochrane Database of Systematic Reviews (2): CD001820. doi:10.1002/14651858.CD001820.pub3. PMID 17636684.
  12. Sprigg N, Gray LJ, England T, et al. (2008). Berger JS, ed. "A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility". PLoS ONE. 3 (8): e2852. doi:10.1371/journal.pone.0002852. PMC 2481397Freely accessible. PMID 18682741.
This article is issued from Wikipedia - version of the 12/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.